Go to
JCI Insight
Citations to this article
Sameer Agnihotri, … , Monika Hegi, Abhijit Guha
Published December 12, 2011
Citation Information: J Clin Invest. 2012;122(1):253-266. https://doi.org/10.1172/JCI59334.
Citation Information: J Clin Invest. 2012;122(1):253-266. https://doi.org/10.1172/JCI59334.
Abstract
Glioblastoma multiforme (GBM) is the most common and lethal of all gliomas. The current standard of care includes surgery followed by concomitant radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ). O6-methylguanine–DNA methyltransferase (MGMT) repairs the most cytotoxic of lesions generated by TMZ, O6-methylguanine. Methylation of the MGMT promoter in GBM correlates with increased therapeutic sensitivity to alkylating agent therapy. However, several aspects of TMZ sensitivity are not explained by MGMT promoter methylation. Here, we investigated our hypothesis that the base excision repair enzyme alkylpurine–DNA–N-glycosylase (APNG), which repairs the cytotoxic lesions N3-methyladenine and N7-methylguanine, may contribute to TMZ resistance. Silencing of APNG in established and primary TMZ-resistant GBM cell lines endogenously expressing MGMT and APNG attenuated repair of TMZ-induced DNA damage and enhanced apoptosis. Reintroducing expression of APNG in TMZ-sensitive GBM lines conferred resistance to TMZ in vitro and in orthotopic xenograft mouse models. In addition, resistance was enhanced with coexpression of MGMT. Evaluation of APNG protein levels in several clinical datasets demonstrated that in patients, high nuclear APNG expression correlated with poorer overall survival compared with patients lacking APNG expression. Loss of APNG expression in a subset of patients was also associated with increased APNG promoter methylation. Collectively, our data demonstrate that APNG contributes to TMZ resistance in GBM and may be useful in the diagnosis and treatment of the disease.
Authors
Sameer Agnihotri, Aaron S. Gajadhar, Christian Ternamian, Thierry Gorlia, Kristin L. Diefes, Paul S. Mischel, Joanna Kelly, Gail McGown, Mary Thorncroft, Brett L. Carlson, Jann N. Sarkaria, Geoffrey P. Margison, Kenneth Aldape, Cynthia Hawkins, Monika Hegi, Abhijit Guha
Total citations by year
Citation information
Citations to this article (97)
| Title and authors | Publication | Year |
|---|---|---|
|
Temozolomide Treatment in Refractory Pituitary Adenomas and Pituitary Carcinomas
Deng C, Yang S, Pu C, Bai X, Tian C, Feng M |
Neuroendocrinology | 2025 |
|
HJURP is recruited to double-strand break sites and facilitates DNA repair by promoting chromatin reorganization.
Serafim RB, Cardoso C, Storti CB, da Silva P, Qi H, Parasuram R, Navegante G, Peron JPS, Silva WA Jr, Espreafico EM, Paçó-Larson ML, Price BD, Valente V |
Oncogene | 2024 |
|
Transformed astrocytes confer temozolomide resistance on glioblastoma via delivering ALKBH7 to enhance APNG expression after educating by glioblastoma stem cells-derived exosomes.
Liu X, Liu L, Wu A, Huang S, Xu Z, Zhang X, Li Z, Li H, Dong J |
CNS Neuroscience & Therapeutics | 2024 |
|
A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance
Karve AS, Desai JM, Gadgil SN, Dave N, Wise-Draper TM, Gudelsky GA, Phoenix TN, DasGupta B, Yogendran L, Sengupta S, Plas DR, Desai PB |
International journal of molecular sciences | 2024 |
|
Origin recognition complex 6 overexpression promotes growth of glioma cells
Yang WL, Zhang WF, Wang Y, Lou Y, Cai Y, Zhu J |
Cell Death and Disease | 2024 |
|
AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma.
Bickerdike MJ, Nafia I, Bessede A, Chen CB, Wangpaichitr M |
BMC Cancer | 2024 |
|
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.
Ahluwalia MS, Ozair A, Drappatz J, Ye X, Peng S, Lee M, Rath S, Dhruv H, Hao Y, Berens ME, Walbert T, Holdhoff M, Lesser GJ, Cloughesy TF, Sloan AE, Takebe N, Couce M, Peereboom DM, Nabors B, Wen PY, Grossman SA, Rogers LR |
Clinical cancer research | 2024 |
|
Human translesion DNA polymerases ɩ and κ mediate tolerance to temozolomide in MGMT-deficient glioblastoma cells
Latancia MT, da Silva Leandro G, Bastos AU, Moreno NC, Ariwoola AB, Martins DJ, Ashton NW, Ribeiro VC, Hoch NC, Rocha CR, Woodgate R, Menck CF |
DNA repair | 2024 |
|
Accidental Encounter of Repair Intermediates in Alkylated DNA May Lead to Double-Strand Breaks in Resting Cells
Fujii S, Fuchs RP |
International Journal of Molecular Sciences | 2024 |
|
A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.
Golbourn B, Ho B, Bondoc A, Luck A, Fan X, Richardson E, Marcellus R, Prakesch M, Halbert M, Agrawal N, Smith C, Huang A, Rutka JT |
Neuro-oncology | 2024 |
|
COL8A1 overexpression promotes glioma cell growth by activating focal adhesion kinase signaling cascade.
Qian J, Xing H, Wang Y, Li C, Chen H, Rong J, Qian C |
NPJ precision oncology | 2024 |
|
METTL3 knockdown promotes temozolomide sensitivity of glioma stem cells via decreasing MGMT and APNG mRNA stability
Shi J, Zhang P, Dong X, Yuan J, Li Y, Li S, Cheng S, Ping Y, Dai X, Dong J |
Cell Death Discovery | 2023 |
|
G protein inhibitory α subunit 2 is a molecular oncotarget of human glioma
Wang Y, Liu F, Wu J, Zhang MQ, Chai JL, Cao C |
International journal of biological sciences | 2023 |
|
A robust luminescent assay for screening alkyladenine DNA glycosylase inhibitors to overcome DNA repair and temozolomide drug resistance
Song YQ, Li GD, Niu D, Chen F, Jing S, Wai Wong VK, Wang W, Leung CH |
Journal of Pharmaceutical Analysis | 2023 |
|
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Ntafoulis I, Kleijn A, Ju J, Jimenez-Cowell K, Fabro F, Klein M, Chi Yen RT, Balvers RK, Li Y, Stubbs AP, Kers TV, Kros JM, Lawler SE, Beerepoot LV, Kremer A, Idbaih A, Verreault M, Byrne AT, O'Farrell AC, Connor K, Biswas A, Salvucci M, Prehn JHM, Lambrechts D, Dilcan G, Lodi F, Arijs I, van den Bent MJ, Dirven CMF, Leenstra S, Lamfers MLM |
British Journal of Cancer | 2023 |
|
Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG.
Nguyen TT, Rajakannu P, Pham MDT, Weman L, Jucht A, Buri MC, Van Dommelen K, Hegi ME |
Molecular Oncology | 2023 |
|
Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications.
Kaina B |
Journal of Clinical Medicine | 2023 |
|
The role of KDM4A‐mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis
Li X, Xu J, Su W, Wu H, Zhao K, Zhang C, Chen X, Yang L |
The Kaohsiung Journal of Medical Sciences | 2023 |
|
Double-Strand Breaks: when DNA Repair Events Accidentally Meet
Fujii S, Sobol RW, Fuchs RP |
DNA repair | 2022 |
|
A DNA repair-independent role for alkyladenine DNA glycosylase in alkylation-induced unfolded protein response
Milano L, Charlier CF, Andreguetti R, Cox T, Healing E, Thomé MP, Elliott RM, Samson LD, Masson JY, Lenz G, Henriques JA, Nohturfft A, Meira LB |
Proceedings of the National Academy of Sciences | 2022 |
|
Base excision repair accessory factors in senescence avoidance and resistance to treatments
Vickridge E, Faraco CC, Nepveu A |
2022 | |
|
The GBM Tumor Microenvironment as a Modulator of Therapy Response: ADAM8 Causes Tumor Infiltration of Tams through HB-EGF/EGFR-Mediated CCL2 Expression and Overcomes TMZ Chemosensitization in Glioblastoma
Liu X, Huang Y, Qi Y, Wu S, Hu F, Wang J, Shu K, Zhang H, Bartsch JW, Nimsky C, Dong F, Lei T |
Cancers | 2022 |
|
The role of RNA modification in the generation of acquired drug resistance in glioma
Yan Y, Wei W, Long S, Ye S, Yang B, Jiang J, Li X, Chen J |
Frontiers in Genetics | 2022 |
|
TIMM44 is a potential therapeutic target of human glioma
Guo YZ, Chen G, Huang M, Wang Y, Liu YY, Jiang Q, Cao C, Liu F |
Theranostics | 2022 |
|
NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity
Chen TC, Minea RO, Swenson S, Yang Z, Thein TZ, Schönthal AH |
Cancers | 2022 |
|
Application of the antitussive agents oxelaidin and butamirate as anti-glioma agents
SJ Lee, SY Yeom, JY Lee, C Park |
Scientific Reports | 2021 |
|
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
M Castro, A Pampana, A Alam, R Parashar, S Rajagopalan, DA Lala, KG Roy, S Basu, A Prakash, P Nair, V Joseph, A Agarwal, P G, L Behura, S Kulkarni, NR Choudhary, S Kapoor |
Journal of Neuro-Oncology | 2021 |
|
Depletion of Kruppel-like factor 15 sensitized gliomas to temozolomide cytotoxicity through O6-methylguanine-DNA methyl-transferase
X Qu, X Liu, Y Zhang, Z Shi, X Wang |
Biochemistry and Biophysics Reports | 2021 |
|
Mouse models of glioblastoma for the evaluation of novel therapeutic strategies
AF Haddad, JS Young, D Amara, MS Berger, DR Raleigh, MK Aghi, NA Butowski |
2021 | |
|
Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53–PUMA Apoptosis Pathway
HC Tsai, KC Wei, PY Chen, CY Huang, KT Chen, YJ Lin, HW Cheng, YR Chen, HT Wang |
Frontiers in Oncology | 2021 |
|
The Multifaceted Role of CMA in Glioma: Enemy or Ally?
AL Dico, C Martelli, C Diceglie, L Ottobrini |
International journal of molecular sciences | 2021 |
|
METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner
J Shi, G Chen, X Dong, H Li, S Li, S Cheng, Y Li, L Wang, J Yuan, Z Qian, J Dong |
Frontiers in Oncology | 2021 |
|
Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy
E Zhou, Y Li, F Wu, M Guo, J Xu, S Wang, Q Tan, P Ma, S Song, Y Jin |
EBioMedicine | 2021 |
|
Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma
R Vengoji, P Atri, MA Macha, P Seshacharyulu, N Perumal, K Mallya, Y Liu, LM Smith, S Rachagani, S Mahapatra, MP Ponnusamy, M Jain, SK Batra, N Shonka |
Journal of Experimental & Clinical Cancer Research | 2021 |
|
Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide
I Gomes, DA Moreno, MB dos Reis, LS da Silva, LF Leal, GM Gonçalves, CA Pereira, MA Oliveira, M de Medeiros Matsushita, RM Reis |
Journal of Neuro-Oncology | 2021 |
|
Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma
CH Chien, WT Hsueh, JY Chuang, KY Chang |
Journal of Biomedical Science | 2021 |
|
Neuronal-driven glioma growth requires Gαi1 and Gαi3
Y Wang, Y Liu, M Chen, KW Cheng, L Qi, Z Zhang, Y Peng, K Li, F Liu, G Chen, C Cao |
Theranostics | 2021 |
|
Forkhead box protein O3a promotes glioma cell resistance to temozolomide by regulating matrix metallopeptidase and β‑catenin
D Sun, S Yang, X Zhang, S Li, L Wang, J Chen, C Qiu, K Xu |
Oncology Letters | 2021 |
|
Genotoxic therapy and resistance mechanism in gliomas
F Lang, Y Liu, F Chou, C Yang |
Pharmacology & Therapeutics | 2021 |
|
Alkyladenine DNA glycosylase deficiency uncouples alkylation-induced strand break generation from PARP-1 activation and glycolysis inhibition
FA Alhumaydhi, D de O. Lopes, DL Bordin, AS Aljohani, CB Lloyd, MD McNicholas, L Milano, CF Charlier, I Villela, JA Henriques, KE Plant, RM Elliott, LB Meira |
Scientific Reports | 2020 |
|
DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance
JF de Sousa, RB Serafim, LM de Freitas, CR Fontana, V Valente |
Genetics and molecular biology | 2020 |
|
Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition
IC Sorribes, SK Handelman, HV Jain |
Journal of The Royal Society Interface | 2020 |
|
Considering the Experimental Use of Temozolomide in Glioblastoma Research
VJ Herbener, T Burster, A Goreth, M Pruss, H von Bandemer, T Baisch, R Fitzel, MD Siegelin, G Karpel-Massler, KM Debatin, MA Westhoff, H Strobel |
Biomedicines | 2020 |
|
Astrocytes Decreased the Sensitivity of Glioblastoma Cells to Temozolomide and Bay 11-7082
SE Pustchi, NG Avci, YM Akay, M Akay |
International journal of molecular sciences | 2020 |
|
Knockdown lncRNA DLEU1 Inhibits Gliomas Progression and Promotes Temozolomide Chemosensitivity by Regulating Autophagy
QL Lv, LC Wang, DC Li, QX Lin, XL Shen, HY Liu, M Li, YL Ji, CZ Qin, SH Chen |
Frontiers in pharmacology | 2020 |
|
Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells
G Serrano-Heras, B Castro-Robles, CM Romero-Sánchez, B Carrión, R Barbella-Aponte, H Sandoval, T Segura |
Scientific Reports | 2020 |
|
Role of Exosomes in the Progression, Diagnosis, and Treatment of Gliomas
J Shi, Y Zhang, B Yao, P Sun, Y Hao, H Piao, |
Medical science monitor : international medical journal of experimental and clinical research | 2020 |
|
HIF1α and p53 Regulated MED30, a Mediator Complex Subunit, is Involved in Regulation of Glioblastoma Pathogenesis and Temozolomide Resistance
Shukla A, Srivastava S, Darokar J, Kulshreshtha R |
Cellular and Molecular Neurobiology | 2020 |
|
Glioblastoma vs temozolomide: can the red queen race be won?
A Arora, K Somasundaram |
Cancer biology & therapy | 2019 |
|
Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models
N Martinez-Velez, M Marigil, M García-Moure, M Gonzalez-Huarriz, JJ Aristu, LI Ramos-García, S Tejada, R Díez-Valle, A Patiño-García, OJ Becher, C Gomez-Manzano, J Fueyo, MM Alonso |
Acta Neuropathologica Communications | 2019 |
|
Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells
JC Chen, IN Lee, C Huang, YP Wu, CY Chung, MH Lee, MH Lin, JT Yang |
BMC Cancer | 2019 |
|
Circular RNA PRKCI promotes glioma cell progression by inhibiting microRNA-545
X Zhang, H Yang, L Zhao, G Li, Y Duan |
Cell Death and Disease | 2019 |
|
Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging
HR Cho, N Kumari, N Thakur, HT Vu, H Kim, SH Choi |
Scientific Reports | 2019 |
|
microRNA-200a downregulation in human glioma leads to Gαi1 over-expression, Akt activation, and cell proliferation
Y Liu, MB Chen, L Cheng, Z Zhang, Z Yu, Q Jiang, G Chen, C Cao |
Oncogene | 2018 |
|
Glioblastoma Survival Outcomes at a Tertiary Hospital in Appalachia: Factors Impacting the Survival of Patients Following Implementation of the Stupp Protocol
O Urhie, R Turner, B Lucke-Wold, W Radwan, J Ahn, K Gyure, S Bhatia |
World Neurosurgery | 2018 |
|
C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma
T Thanasupawat, A Glogowska, M Burg, J Krcek, J Beiko, M Pitz, GJ Zhang, S Hombach-Klonisch, T Klonisch |
Molecular Oncology | 2018 |
|
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
LV Syro, F Rotondo, M Camargo, LD Ortiz, CA Serna, K Kovacs |
Frontiers in Endocrinology | 2018 |
|
Treatment of Glioblastoma in the Elderly
RA Harrison, JF de Groot |
Drugs & Aging | 2018 |
|
Long Non-Coding RNAs in Gliomas: From Molecular Pathology to Diagnostic Biomarkers and Therapeutic Targets
M Vecera, J Sana, R Lipina, M Smrcka, O Slaby |
International journal of molecular sciences | 2018 |
|
PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma
MA Sharpe, S Raghavan, DS Baskin |
Oncotarget | 2018 |
|
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
MA Calegari, A Inno, S Monterisi, A Orlandi, D Santini, M Basso, A Cassano, M Martini, T Cenci, I Pascalis, F Camarda, B Barbaro, LM Larocca, S Gori, G Tonini, C Barone |
British Journal of Cancer | 2017 |
|
APNG as a prognostic marker in patients with glioblastoma
S Fosmark, S Hellwege, RH Dahlrot, KL Jensen, H Derand, J Lohse, MD Sørensen, S Hansen, BW Kristensen, AB Hjelmeland |
PloS one | 2017 |
|
Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines
C Aaberg-Jessen, L Fogh, MD Sørensen, B Halle, N Brünner, BW Kristensen |
Pathology & Oncology Research | 2017 |
|
PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation
A Gupta, S Anjomani-Virmouni, N Koundouros, M Dimitriadi, R Choo-Wing, A Valle, Y Zheng, YH Chiu, S Agnihotri, G Zadeh, JM Asara, D Anastasiou, MJ Arends, LC Cantley, G Poulogiannis |
Molecular Cell | 2017 |
|
CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide
S Kaur, ZM Ramdzan, MC Guiot, L Li, L Leduy, D Ramotar, S Sabri, B Abdulkarim, A Nepveu |
Neuro-Oncology | 2017 |
|
Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
SH Kizilbash, SK Gupta, K Chang, R Kawashima, KE Parrish, BL Carlson, KK Bakken, AC Mladek, MA Schroeder, PA Decker, GJ Kitange, Y Shen, Y Feng, AA Protter, WF Elmquist, JN Sarkaria |
Molecular cancer therapeutics | 2017 |
|
Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
S Valtorta, AL Dico, I Raccagni, D Gaglio, S Belloli, LS Politi, C Martelli, C Diceglie, M Bonanomi, G Ercoli, V Vaira, L Ottobrini, RM Moresco |
Oncotarget | 2017 |
|
Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51
E Xipell, T Aragón, N Martínez-Velez, B Vera, MA Idoate, JJ Martínez-Irujo, AG Garzón, M Gonzalez-Huarriz, AM Acanda, C Jones, FF Lang, J Fueyo, C Gomez-Manzano, MM Alonso |
Neuro-Oncology | 2016 |
|
Temozolomide resistance in glioblastoma multiforme
SY Lee |
Genes & Diseases | 2016 |
|
Old chemotherapy makes a comeback: dual alkylator therapy for pediatric high-grade glioma
E Bouffet, V Ramaswamy |
Neuro-Oncology | 2016 |
|
Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells
J Hu, J Wang, G Wang, Z Yao, X Dang |
International journal of molecular medicine | 2016 |
|
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
CR Rocha, GS Kajitani, A Quinet, RS Fortunato, CF Menck |
Oncotarget | 2016 |
|
Naturally occurring polyphenol, morin hydrate, inhibits enzymatic activity of N-methylpurine DNA glycosylase, a DNA repair enzyme with various roles in human disease
M Dixon, J Woodrick, S Gupta, SK Karmahapatra, S Devito, S Vasudevan, S Dakshanamurthy, S Adhikari, VM Yenugonda, R Roy |
Bioorganic & Medicinal Chemistry | 2015 |
|
O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma
MS Bobola, M Alnoor, JY Chen, DD Kolstoe, DL Silbergeld, RC Rostomily, A Blank, MC Chamberlain, JR Silber |
BBA Clinical | 2015 |
|
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
RK Balvers, ML Lamfers, JJ Kloezeman, A Kleijn, LM Pont, CM Dirven, S Leenstra |
Journal of Translational Medicine | 2015 |
|
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma
H Shao, J Chung, K Lee, L Balaj, C Min, BS Carter, FH Hochberg, XO Breakefield, H Lee, R Weissleder |
Nature Communications | 2015 |
|
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment
H He, M Yao, W Zhang, B Tao, F Liu, S Li, Y Dong, C Zhang, Y Meng, Y Li, G Hu, C Luo, H Zong, Y Lu |
Cellular and Molecular Immunology | 2015 |
|
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide
JL McFaline-Figueroa, CJ Braun, M Stanciu, ZD Nagel, P Mazzucato, D Sangaraju, E Cerniauskas, K Barford, A Vargas, Y Chen, N Tretyakova, JA Lees, MT Hemann, FM White, LD Samson |
Cancer research | 2015 |
|
Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines
JC Anderson, CW Duarte, K Welaya, TD Rohrbach, M Bredel, ES Yang, NV Choradia, JV Thottassery, GY Gillespie, JA Bonner, CD Willey |
Radiotherapy and Oncology | 2014 |
|
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide
L Tentori, L Ricci-Vitiani, A Muzi, F Ciccarone, F Pelacchi, R Calabrese, D Runci, R Pallini, P Caiafa, G Graziani |
BMC Cancer | 2014 |
|
Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls
RH Dahlrot, MD Sørensen, AM Rosager, S Hellwege, JA Bangsø, T Rosenberg, SA Petterson, J Klitkou, S Fosmark, S Hansen, BW Kristensen |
CNS Oncology | 2014 |
|
Contemporary murine models in preclinical astrocytoma drug development
RS McNeill, M Vitucci, J Wu, CR Miller |
Neuro-Oncology | 2014 |
|
ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents
S Agnihotri, K Burrell, P Buczkowicz, M Remke, B Golbourn, Y Chornenkyy, A Gajadhar, NA Fernandez, ID Clarke, MS Barszczyk, S Pajovic, C Ternamian, R Head, N Sabha, RW Sobol, MD Taylor, JT Rutka, C Jones, PB Dirks, G Zadeh, C Hawkins |
Cancer Discovery | 2014 |
|
Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
SK Gupta, AC Mladek, BL Carlson, F Boakye-Agyeman, KK Bakken, SH Kizilbash, MA Schroeder, J Reid, JN Sarkaria |
Clinical cancer research | 2014 |
|
Aag DNA glycosylase promotes alkylation-induced tissue damage mediated by Parp1
JA Calvo, CA Moroski-Erkul, A Lake, LW Eichinger, D Shah, I Jhun, P Limsirichai, RT Bronson, DC Christiani, LB Meira, LD Samson |
PLoS genetics | 2013 |
|
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments
K Masui, B Gini, J Wykosky, C Zanca, PS Mischel, FB Furnari, WK Cavenee |
Carcinogenesis | 2013 |
|
Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective
B Wiestler, R Claus, SA Hartlieb, MG Schliesser, EK Weiss, T Hielscher, M Platten, LM Dittmann, C Meisner, J Felsberg, C Happold, M Simon, G Nikkhah, K Papsdorf, JP Steinbach, M Sabel, C Grimm, D Weichenhan, B Tews, G Reifenberger, D Capper, W Muller, C Plass, M Weller, W Wick |
Neuro-Oncology | 2013 |
|
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma
XY Liu, L Zhang, J Wu, L Zhou, YJ Ren, WQ Yang, ZJ Ming, B Chen, J Wang, Y Zhang, JM Yang |
PloS one | 2013 |
|
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
N Thon, S Kreth, FW Kreth |
OncoTargets and therapy | 2013 |
|
Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas
MF Chiang, PY Chou, WJ Wang, CI Sze, NS Chang |
Frontiers in Oncology | 2013 |
|
In search of molecular markers of glioma in elderly patients
ME Hegi, R Stupp |
Nature Reviews Neurology | 2013 |
|
Aspirin‐/ TMZ ‐coloaded Microspheres Exert Synergistic Antiglioma Efficacy via Inhibition of β‐catenin Transactivation
ZD Shi, XM Qian, CY Liu, L Han, KL Zhang, LY Chen, JX Zhang, PY Pu, XB Yuan, CS Kang |
CNS Neuroscience & Therapeutics | 2012 |
|
Emerging insights into the molecular and cellular basis of glioblastoma
GP Dunn, ML Rinne, J Wykosky, G Genovese, SN Quayle, IF Dunn, PK Agarwalla, MG Chheda, B Campos, A Wang, C Brennan, KL Ligon, F Furnari, WK Cavenee, RA Depinho, L Chin, WC Hahn |
Genes & development | 2012 |
|
The strategy for enhancing temozolomide against malignant glioma
M Nakada, T Furuta, Y Hayashi, T Minamoto, JI Hamada |
Frontiers in Oncology | 2012 |
|
Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide
MS Bobola, DD Kolstoe, A Blank, MC Chamberlain, JR Silber |
Frontiers in Oncology | 2012 |
|
Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
K Yoshimoto, M Mizoguchi, N Hata, H Murata, R Hatae, T Amano, A Nakamizo, T Sasaki |
Frontiers in Oncology | 2012 |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)